跳到主要內容

全部

#

魏凌鴻Lin-Hung Wei 我要掛號 回列表

專任教授,主治醫師

婦科腫瘤手術微創手術抗癌新藥物腫瘤細胞分子生物學腫瘤血管新生學光動力治療

  • 台大醫學院婦產科 專任教授 --迄今
  • 國立台灣大學 醫學系 醫學士 -
    國立台灣大學醫學院 毒理學研究所 博士 -
    國立台灣大學 管理學院 高階管理碩士(EMBA 93B 生物科技管理組) -
  • 台大醫院婦產部 住院醫師 -
    台大醫院腫瘤醫學部 主治醫師 -
    台大醫院腫瘤醫學部 腫瘤外科主任 -
    法國巴黎居里研究所(Institute Curie) 研究員 -
    美國紐約Roswell Park Cancer Institute 研究員 -
    • 亞洲臨床腫瘤醫學會優秀論文獎
    • 台灣癌症聯合學術年會優秀論文獎
    • 中華民國婦產科醫學會「徐千田優秀論文獎」
    • 中華民國婦產科醫學會「李鎡堯優秀論文獎」
    • 日本婦產科醫學會優秀論文獎
    • 1. Interleukin-6 and Cervical Cancer: the Relationship with Vascular Endothelial Growth Factor. Gynecologic Oncology 82(1): 49-56, 2001

    • 2. The Anti-Apoptotic Role of Interleukin-6 In Human Cervical Cancer Is Mediated by Up-Regulation of Mcl-1 Through a PI 3-K/Akt Pathway. Oncogene 20: 5799-5809, 2001

    • 3. Interleukin-6 Promotes Cervical Tumor Growth by VEGF-Dependent Angiogenesis via a STAT3 Pathway. Oncogene 22:1517-1527, 2003

    • 4. Cyclooxygenase-2 Induces EP1- and HER-2/Neu-Dependent Vascular Endothelial Growth Factor-C Up-Regulation: A Novel Mechanism of Lymphangiogenesis in Lung Adenocarcinoma. Cancer Research 64(2): 554-564, 2004

    • 5. Overexpression of Her-2/neu in Epithelial Ovarian Carcinoma Induces Vascular Endothelial Growth Factor C by Activating NF-B: Implications for Malignant Ascites Formation and Tumor Lymphangiogenesis. Journal of Biomedical Science 11(2): 249-259, 2004

    • 6. Arsenic Trioxide Prevents Radiation-Enhanced Tumor Invasiveness and Inhibits Matrix Metalloproteinase-9 through Down-Regulation of Nuclear Factor kB. Oncogene 24: 390-399, 2005

    • 7. Up-Regulation of Interleukin-6 in Human Ovarian Cancer Cell via a Gi/ PI3K/ NF-kB Pathway by Lysophosphatidic Acid, An Ovarian Cancer Activating Factor. Carcinogenesis 26(1): 45-52, 2005

    • 8. A Novel Peptide Specifically Binding to Interleukin-6 Receptor (gp80) Inhibits Angiogenesis and Tumor Growth. Cancer Research 65(11): 4827-4835, 2005

    • 9. Interleukin-6 Trans Signaling Enhances Photodynamic Therapy by Modulating Cell Cycling. British Journal of Cancer 97(11):1513-  1522, 2007

    • 10. Phase II Trial of Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox®) in Recurrent Platinum-Sensitive Ovarian Cancer Following Primary Therapy with Paclitaxel and Platinum. Gynecologic Oncology 112(1): 35-39, 2009

    • 11. IL-6 Trans-signaling in Malignant Ascites Formation and Progression in Ovarian Cancer. Cancer Research 71(2):424-434, 2011

    • 12. Histone Deacetylase 6 Regulates Estrogen Receptor a in Uterine Leiomyoma. Reproductive Sciences 18(8):755-762, 2011

    • 13. The Role of IL-6 Trans-Signaling in Vascular Leakage: Implications for Ovarian Hyperstimulation Syndrome in a Murine Model. J Clin Endocrinol Metab 98(3):E472-84, 2013

    • 14. Arsenic Trioxide Inhibits CXCR4-Mediated Metastasis by Interfering miR-520h/PP2A/NF-kB Signaling in Cervical Cancer. Ann Surg Oncol. 21 Suppl 4:S687-95, 2014.

    • 15. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer. 13:189, 2014.

    • 16. The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer. Ann Surg Oncol. 22 Suppl 3:S1556-65, 2015.

    • 17. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res. 77(8):1955-1967, 2017.

    • 18. Activation of STAT3 and STAT5 signaling in epithelial ovarian cancer progression: mechanism and therapeutic opportunity. Cancers, 12 (1): 24, 2020

    • 19. Long-term follow-up of 453 patients with pelvic organ prolapse who underwent transvaginal sacrospinous colpopexy with Veronikis ligature carrier. Sci Rep.10(1):4997, 2020